Neumann Capital Management LLC Grows Position in Pfizer Inc. $PFE

Neumann Capital Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 26.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,588 shares of the biopharmaceutical company’s stock after purchasing an additional 6,000 shares during the quarter. Neumann Capital Management LLC’s holdings in Pfizer were worth $693,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $23.75 on Friday. The company has a market cap of $135.03 billion, a P/E ratio of 12.63, a PEG ratio of 0.77 and a beta of 0.55. The stock has a fifty day moving average price of $24.55 and a 200 day moving average price of $24.13. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the business earned $0.60 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on PFE. Bank of America lifted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.